Do Statins Help Prevent VTE After Hemorrhagic Stroke During the Acute Period?

Jung Hyun Park¹, Kwang Wook Jo², Hoon Kim²

¹Department of Neurosurgery, Dongtan Sacred Heart Hospital, Hallym University Medical Center, Hwaseong, Korea
²Department of Neurosurgery, Bucheon St. Mary’s Hospital, The Catholic University of Korea, Bucheon, Korea

Objectives
The effect of statins on venous thromboembolism (VTE) especially pulmonary embolism (PE) is debatable. This study investigated whether statin medication can decrease the occurrence of VTE in patients with hemorrhagic stroke during the acute period.

Methods
This is a retrospective study of patients with hemorrhagic stroke between March 2011 and December 2013. Patients with newly diagnosed hemorrhagic stroke were observed during 6 weeks of hospitalization. Occurrence determined using Doppler ultrasound and computed angiography was used to assess risk factors of VTE in patients with hemorrhagic stroke during the acute period. The difference and incidence of the VTE among acute hemorrhagic stroke was analysed in patients who did not receive statin medication, who received statin medication after the current hemorrhagic stroke, and who received statin medication after previous hemorrhagic stroke.

Results
Among 98 patients, 9 (9.2%) patients representing 3 from each group had VTE (6 for deep vein thrombosis and 3 for PE) during the follow-up. Each incidence of VTE was 6.4%, 13.6%, and 10.3% in patients who did not receive statins, who received statin medication after the current hemorrhagic stroke, and who received statin medication after previous hemorrhagic stroke, respectively (p>0.05).

Conclusions
Moderate intensity dose of statin use was not associated with a reduced risk of VTE in patients with hemorrhagic stroke, especially in the acute period. Randomized, placebo-controlled trials are needed to evaluate the potential benefits of lipid-lowering statin in the prevention of venous thromboembolism in patients with hemorrhagic stroke.

Keywords: Intracranial Hemorrhage; Neurocritical care; Pulmonary embolism; Statin; Venous thromboembolism
INTRODUCTION

Venous thromboembolism (VTE) is a common disease affecting more than one per 1000 persons each year\(^{(7)}\). Patients with hemorrhagic stroke have a relatively high risk of VTE because of immobility and increased prothrombotic activity\(^{(1)}\). Current guidelines recommend pharmacologic prophylaxis using heparin or low-molecular heparin (LMWH). However many neurosurgeon and neurologist worried about intracerebral hematoma expansion when.

Statins represent a mainstay in the prevention of arterial events. However, two recent meta-analyses suggested that statins may also reduce the incidence of VTE by 10-20\(^{(3)}\). The ability to decrease tissue factor expression offers a biological rational for statin's anti-thrombotic effect\(^{(2)}\). These studies showed that statin medication for more than 3 months helps prevent VTE\(^{(3,15)}\).

The influence of statins in preventing deep vein thrombosis (DVT) in the acute period could not be explained by these studies since DVT typically develops 2 to 7 days after stroke onset, with about 80% of all DVTs occurring within the first 10 days following a stroke\(^{(3,18)}\). In cochrane database systematic review in 2014, rosuvastatin was associated with a reduced incidence of VTE although the available date were limited.

The incidence of deep vein thrombosis (DVT) during the first two weeks after stroke ranges from 10% to 75% in untreated patients\(^{(19,21)}\). Pulmonary embolism (PE) is the most common cause of death between the first two and four weeks after AIS\(^{(20)}\).

We hypothesised that statin therapy may have a role in VTE prevention in patients with hemorrhagic stroke. We conducted this study to explore the association between moderate intensity statin use and VTE in patients with hemorrhagic stroke during the acute period.

METHODS

Study population and data collection

This retrospective cohort study was at a university-affiliated hospital. The study protocol was approved by the Institutional Review Board of Bucheon St. Mary’s Hospital at the Catholic University of Korea (No. HC13RISE0120). Patients with acute hemorrhagic stroke between March 2011 and December 2013 were enrolled.

Demographic characteristics, risk factors, baseline laboratory results on the day of admission [blood cell count, blood urea nitrogen (BUN)-creatinine (Cr) ratio, osmolarity and C-reactive protein (CRP)], and treatment method data were obtained from the stroke database. The severity of the neurological deficit was evaluated according to the National Institutes of Health Stroke Scale (NIHSSS) in the emergency room. Volume of the intracerebral haematoma was calculated using the formula: ABC/2, where A, B, and C represent the largest dimensions of the haematoma measured at perpendicular angles to one another. Experienced rehabilitation staff checked the severity of weakness by manual muscle test (MMT). MMT results were classified as grade 5 (movement against gravity plus full resistance), grade 4 (movement against gravity plus some resistance), grade 3 (complete range of motion against gravity with no resistance), grade 2 (full or partial range of motion with no gravity), grade 1 (slight contractility without any movement), and grade 0 (no evidence of contractility; complete paralysis).

Inclusion criteria and exclusion criteria

Inclusion criteria were age > 18 years, hemorrhagic stroke as confirmed by computed tomography (CT) or magnetic resonance imaging (MRI), onset hemorrhagic stroke within the prior 3 days, and availability for 6 weeks closed observation during hospitalisation. Exclusion criteria were ischaemic stroke; age < 18 years; hemorrhagic stroke with vascular anomalies including intracranial aneurysmal rupture, haemorrhage from arterio-venous malformation, or tumorous bleeding; use of anti-platelet medication; discharge or death within 6 week; comorbidities influencing the neurological status, such as seizures or acute respiratory distress; severe stroke (NISSS score ≥ 20); immobility before stroke onset; and use of hormone replacement therapy.

Diagnosis of VTE and treatment

Doppler ultrasound with the criterion of venous compressibility with transducer and computed DVT angiography were used to diagnose DVT of femoral and popliteal veins. Computed pulmonary angiography with the presence of pulmonary emboli or high probability on ventilation-perfusion scan was used to diagnose pulmonary embolism (PE). All of these diagnostic tools were only used for patients who complained of VTE-suspicious symptoms including pain, tenderness, swelling, warmth, distension of surface veins, Luck’s sign in one or both legs, cyanosis, chest pain, and respiratory distress. Prophylactic use of heparin was not routinely used during the admission period because of concern about hematoma expansion. Thromboembolic deterrent stockings were applied. Early exercise was done 3 days after admission. Patients diagnosed with DVT were treated with full doses of low-molecular-weight heparin. An inferior vena cava filter was also placed, if needed.
Identification of statin use and patient classification

The patients were asked about their current medication including the information on the use of statins. Additionally, medical reports of patients were reviewed to verify the information on the use of statin. Patients were classified into three groups: 1) no statin medication 2) moderate intensity statin use after hemorrhagic stroke, and 3) moderate intensity statin use prior to hemorrhagic stroke.

Moderate stains were defined as atorvastatin 10 mg or 20 mg, rosuvastatin 10 mg and pravastatin 40 mg.

Statistical analyses

Statistical analyses used the Statistical Package for Social Sciences version 18 (SPSS, Chicago, Illinois, USA). Characteristics of hemorrhagic stroke patients with and without VTE were analysed. Variable characteristics were expressed numerically and as percentages. The Mann-Whitney test was used to compare continuous variables like age and body mass index. Fisher’s exact test and chi-squared test were used to compare dichotomous variables including gender, smoking, alcohol, diabetes, hypertension, characteristics of hemorrhage, initial national institute of health stroke scale (NIHSS), severity of muscle weakness, and statin medication. A p value < 0.05 was considered statistically significant.

RESULTS

Patients and radiologic findings

There were 167 patients with acute hemorrhagic stroke. Among them, 98 (40 female and 58 male) patients were included in this study. Of these 98 patients, 9 (9.2%) patients had VTE (6 for DVT and 3 for PE) during the follow-up period. Overall mean age was 59.6 years (range, 19 to 89 years). The mean age of patients with VTE and without VTE was 64 and 59.1 years, respectively (p = 0.322). Medical and social conditions such as smoking, alcohol consumption, diabetes and hypertension were evaluated relationship of VTE and PE. There were no relationships. Radiologic finding such as amount of hematoma and location also was not associated development of VTE and PE. Inflammatory marker and dehydration status on admission were no correlation with VTE and PE. The baseline clinical and demographic characteristic of the patients were summarized in Table 1.

Moderate statin use and VTE

Atorvastatin 10 mg (18 patients), atorvastatin 20 mg (5 patients), rosuvastatin 10 mg (14 patients) and pravastatin 40 mg (14 patients) were used. Twenty nine patients were taking these statin to hemorrhagic stroke, 22 patients were taken statin after hemorrhagic stroke. The other patients (47 patients) were not taken before and after hemorrhagic stroke. The numbers of patients who had VTE was the same (n = 3) in each of the three

Table 1. Baseline clinical and demographic characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No VTE (n=89)</th>
<th>VTE (n=9)</th>
<th>p-value</th>
<th>Odds ratio</th>
<th>95% Confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td></td>
<td></td>
<td>0.73</td>
<td>0.27</td>
<td>0.01-11.22</td>
</tr>
<tr>
<td>Smoking</td>
<td>24 (96.0%)</td>
<td>1 (4.0%)</td>
<td>0.44</td>
<td>7.09</td>
<td>0.21-235.09</td>
</tr>
<tr>
<td>Alcohol consumption</td>
<td>53 (91.4%)</td>
<td>5 (8.6%)</td>
<td>0.05</td>
<td>0.36</td>
<td>0.04-3.54</td>
</tr>
<tr>
<td>Diabetes</td>
<td>14 (100.0%)</td>
<td>0 (0.0%)</td>
<td>0.35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>43 (91.5%)</td>
<td>4 (8.5%)</td>
<td>1.00</td>
<td>3.24</td>
<td>0.28-38.20</td>
</tr>
<tr>
<td>Location of haemorrhage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deep brain*</td>
<td>60 (88.2%)</td>
<td>8 (11.8%)</td>
<td>0.58</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebellum</td>
<td>6 (100.0%)</td>
<td>0 (0.0%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others†</td>
<td>23 (95.8%)</td>
<td>1 (4.2%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amount of haemorrhage†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Over 50 cc</td>
<td>75 (91.5%)</td>
<td>7 (8.5%)</td>
<td>0.64</td>
<td>2.33</td>
<td>0.01-485.40</td>
</tr>
<tr>
<td>Laboratory values (g/dL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemoglobin less than 12</td>
<td>20 (95.2%)</td>
<td>1 (4.8%)</td>
<td>0.68</td>
<td>0.39</td>
<td>0.01-20.02</td>
</tr>
<tr>
<td>ESR, less than 20</td>
<td>58 (89.2%)</td>
<td>7 (10.8%)</td>
<td>0.71</td>
<td>0.45</td>
<td>0.03-7.06</td>
</tr>
<tr>
<td>CRP, less than 5</td>
<td>60 (89.6%)</td>
<td>7 (10.4%)</td>
<td>0.72</td>
<td>3.09</td>
<td>0.14-66.34</td>
</tr>
<tr>
<td>BUN/creatinine, less than 15</td>
<td>52 (88.1%)</td>
<td>7 (11.9%)</td>
<td>0.31</td>
<td>0.78</td>
<td>0.07-9.10</td>
</tr>
<tr>
<td>Osmolality, less than 300</td>
<td>40 (93.0%)</td>
<td>3 (7.0%)</td>
<td>0.73</td>
<td>2.26</td>
<td>0.22-23.48</td>
</tr>
</tbody>
</table>

VTE: venous thromboembolism; ESR: erythrocyte sedimentation rate; CRP: c-reactive protein; BUN: blood urea nitrogen.
*Thalamus, basal ganglia, and brain stem were involved in this criterion.
†Pure ventricular hemorrhage and cortical hemorrhage were involved.
‡The formula ABC/2 was used, where A is the greatest hemorrhage diameter by CT, B is the diameter 90 degree to A, and C is the number of CT slices.
groups. Moderate intensity statin use was not significantly associated with VTE reduction (Table 2; p = 0.539). Also, there was no significant relationship (p = 1.000), when patients with acute hemorrhagic stroke were grouped as statin medication and no medication group.

Severity of muscle weakness, active physical therapy
Table 3 shows how severity of muscle weakness influenced prevention of VTE. Thirty three patients had their lower extremities weakness less than grade 2, and 4 (12.1%) patients had VTE, while 5 (7.7%) patients had VTE among 65 patients whose weakness were more than grade 3. These differences were not significant (p = 0.480). Also, among 9 patients who had VTE, 7 participated in active physical therapy 2 weeks following hemorrhagic stroke. Only 2 (6.5%) patients had VTE among 31 patients who had received active physical therapy within 2 weeks of hemorrhagic stroke. These differences were not significant (p = 0.831). Length of stay in the neuro-intensive care unit was not significant.

DISCUSSION
DVT develops most often between days 2 and 7 after stroke onset; about 80% of all DVTs occur within the first 10 days3,16. DVT was reported in 0.74% patients with ischemic stroke and 1.37% of those with hemorrhagic stroke11. In the International Stroke Trial (IST), 0.8% of patients who did not receive thrombosis prophylaxis developed a clinically apparent PE within 2 weeks after stroke onset7. In one study, PE occurred in 0.51% of ischemic stroke patients and 0.68% of hemorrhagic stroke patients from private hospitals in the United States41. There are few reports on the incidence of PE among Asian stroke patients. The 1997 Chinese Acute Stroke Trial reported PE in 12 (0.1%) of 10,335 ischemic stroke patients who took aspirin for 4 weeks1. Little data concerning hemorrhagic stroke in Asia have been published subsequent to this trial. In our study, 9 (9.2%) patients had VTE (6 for DVT and 3 for PE) during the follow-up period. This incidence was relative low compared with previous study because our study was included only symptomatic patients20. The difference between ischemic and hemorrhagic stroke is the result of less preventive management. DVT can occur about twice as often after hemorrhagic stroke then after ischemic stroke2.

Risk factors of VTE such as older age, obesity, cigarette smoking, hormonal replacement, pregnancy, previous medical illness (such as cancer, COPD, congestive heart failure, thrombophilia, smoking, and hypertension), stroke with limb paresis, and recent surgery were generally accepted22. In recent study, Kim et al proposed that dehydration status in patients with ischemic stroke might be a significant independent risk factor for VTE. In this study, dehydration status, limb weakness and other medical illness were not associated with VTE or PE.

Statins are currently considered the most effective cholesterol-lowering drugs. In addition to lipid-lowering effects, statins have anti-inflammatory effects, reduce serum inflammatory markers, and enhance vascular endothelial function5,14,15. Statins have cholesterol-independent pleiotropic effects that exert vascular protection by improving endothelial function, regulating angiogenesis, stabilising arteriosclerotic plaques, and reducing thrombogenic and inflammatory responses15. Statins also have

### Table 2. Influence of moderate intensity statins on prevention of VTE

<table>
<thead>
<tr>
<th></th>
<th>No VTE group (n=89)</th>
<th>VTE group (n=9)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statin medication prior to hemorrhagic stroke</td>
<td>26 (89.7%)</td>
<td>3 (10.3%)</td>
<td>0.54</td>
</tr>
<tr>
<td>Statin medication after hemorrhagic stroke</td>
<td>19 (86.4%)</td>
<td>3 (13.6%)</td>
<td></td>
</tr>
<tr>
<td>No statin medication</td>
<td>44 (93.6%)</td>
<td>3 (6.4%)</td>
<td></td>
</tr>
</tbody>
</table>

VTE: venous thromboembolism.

### Table 3. Influence of muscle weakness and active ambulation on prevention of VTE

<table>
<thead>
<tr>
<th></th>
<th>No VTE group (n=89)</th>
<th>VTE group (n=9)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severity of muscle weakness*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weakness 0-2</td>
<td>29 (87.9%)</td>
<td>4 (12.1%)</td>
<td>0.48</td>
</tr>
<tr>
<td>Weakness 3-5</td>
<td>60 (92.3%)</td>
<td>5 (7.7%)</td>
<td></td>
</tr>
<tr>
<td>Active physical therapy within 2 weeks</td>
<td>29 (93.5%)</td>
<td>2 (6.5%)</td>
<td>0.83</td>
</tr>
<tr>
<td>Length of stay neuro-intensive care unit over 2 weeks</td>
<td>34 (89.5%)</td>
<td>4 (10.5%)</td>
<td>0.36</td>
</tr>
</tbody>
</table>

VTE: venous thromboembolism.

*Grade 0: No muscle movement, Grade 1: Trace of contraction, but no movement at the joint, Grade 2: Movement at the joint with gravity eliminated, Grade 3: Movement against gravity, but not against added resistance, Grade 4: Movement against external resistance, but less than normal, Grade 5: Normal strength.
an anti-coagulation effect by decreasing tissue factor expression, which reduces thrombin generation and attenuates fibrinogen cleavage and factor V/XIII activation\(^5\). Thus, statins improve endothelial thromboembolism expression, resulting in increased protein C activation and factor Va inactivation\(^5\). Although statins have been associated with a reduced risk of VTE in the general population and ischaemic stroke patients\(^6,12,18\), their effect on the incidence of VTE in patients with hemorrhagic stroke has not been studied. Presently, the evidence of use of statins in hemorrhagic stroke was not significant. Although all patients were taking an average dose of statins (< 80 mg of fluvastatin; < 40 mg of lovastatin, simvastatin, or atorvastatin; and < 10 mg of rosuvastatin), statin use was not associated with a lowered risk of developing VTE (\(p = 0.539\)). A recent study reported that statin use was associated with developing VTE and high-dose statin use appeared related to lower occurrence of VTE compared with standard-dose statin use\(^4\). However, the latter study concerned the relationship between atherosclerosis and VTE, not hemorrhagic stroke. In our study, only moderate intensity statin (atorvastatin 10 mg or 20 mg, rosuvastatin 10 mg, pravastatin 40 mg) users were included for decreasing side effect of statin. Our study showed that moderate intensity dose of statin use was not associated with a reduced risk of VTE in patients with hemorrhagic stroke, especially in the acute period.

Our study has several limitations. First, the sample size was small and the control group was retrospectively selected only with suspicious symptoms and excluded patients with severe stroke (NIHSS ≥ 20) or a short hospital stay, regardless of the reason. These reasons lead to inaccurate incidence of VTE and PE in patients with haemorrhagic stroke. Second there was a lack of uniformity in the thromboprophylaxis administered to the patients. Lastly, we could not study the relationship between VTE and statin dosage since all patients receiving an average dose. We did not consider high doses. These limitations should be taken into consideration and need to be addressed in future studies. Nonetheless, the present findings suggest that statin use, especially moderate intensity doses, in patients with hemorrhagic stroke does not decrease the occurrence and risk of VTE.

Many patients after hemorrhagic stroke had permanent neurologic deficits especially limb weakness because limb weakness and immobilization were powerful risk factors\(^22\). Also currently recommended pharmacologic prophylaxis by LMWH or heparin could not use after discharge daily. So we need other pharmacologic prophylaxis in these patients. Information about anti-platelet therapy for the prevention of VTE is scarce. A Cochrane review of two small trials including 133 patients (fewer than 0.3% of the participants included in the overall review) showed that anti-platelet therapy did not reduce the risk of VTE\(^7\). However, aspirin in the acute stage of ischaemic stroke is associated with a reduction in recurrent stroke and is not associated with an excess of intracerebral hemorrhage\(^7\). Statin plus aspirin can reduce risk of VTE in patients with ovarian cancer\(^10\). However, anti-platelet medication to patients with acute hemorrhagic stroke would be criticized for risk of rebleeding. So, we should consider whether we could use anti-platelet medication to patients with acute hemorrhagic stroke for preventing VTE.

CONCLUSION

Moderate-intensity dose of statin use is not associated with a reduced risk of VTE in patients with hemorrhagic stroke in the acute period. Randomized, placebo-controlled trials are needed to evaluate the potential benefits of lipid-lowering statin in the prevention of venous thromboembolism in patients with hemorrhagic stroke.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

NOTES

Ethical approval

the study protocol was approved by the Institutional Review Board of the College of Medicine of The Catholic University of Korea (HC14RISI0035).

Author contributions

Jung Hyun Park analyzed the data, and drafted and revised the manuscript. Hoon Kim analyzed the data, and drafted and revised the manuscript. Thigh-length versus below-knee stockings for

REFERENCES

2. CLOTS (Clots in Legs Or sTockings after Stroke) Trial Collaboration. Thigh-length versus below-knee stockings for


